Gov. Gavin Newsom is proposing reinstating an 'asset test' that would narrow eligibility for low-income seniors and adults ...

FINEOS Corporation announced today that Medavie Blue Cross, a leading benefits provider for health, drug and disability insurance, has successfully commenced managing Individual Life and Disability ...

The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being ...

Disability was assessed at admission, and 6 and 12 months using the GBS Disability Scale proposed by Hughes 11. A TRF was defined as 5: a) improvement in the GBS disability score of at least one grade ...

SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III ...

Also Read: Mid-Cap Firm Annexon’s Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of ...

Last summer, Annexon announced that the therapy then known as ANX005 had met the study’s primary endpoint by achieving a 2.4-fold improvement in GBS disability ... the 12-point scale at Week ...

The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being in a ...